Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy

A. Lehotzky, N. Tokési, I. Gonzalez-Alvarez, V. Merino, M. Bermejo, F. Orosz, P. Lau, G. G. Kovacs, J. Ovádi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Cancer continues to be one of the major health and socio-economic problems worldwide, despite considerable efforts to improve its early diagnosis and treatment. The identification of new constituents as biomarkers for early diagnosis of neoplastic cells and the discovery of new type of drugs with their mechanistic actions are crucial to improve cancer therapy. New drugs have entered the market, thanks to industrial and legislative efforts ensuring continuity of pharmaceutical development. New targets have been identified, but cancer therapy and the anti-cancer drug market still partly depend on anti-mitotic agents. The objective of this paper is to show the effects of KAR-2, a potent anti-mitotic compound, and TPPP/p25, a new unstructured protein, on the structural and functional characteristics of the microtubule system. Understanding the actions of these two potential effectors on the microtubule system could be the clue for early diagnosis and improvement of cancer therapy.

Original languageEnglish
Pages (from-to)3599-3617
Number of pages19
JournalPhilosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences
Volume366
Issue number1880
DOIs
Publication statusPublished - Oct 13 2008

Fingerprint

pharmacology
Pharmacology
Therapy
therapy
Cancer
Drugs
drugs
cancer
Microtubules
Biomarkers
Drug products
effectors
Health
biomarkers
Proteins
Pharmaceuticals
Economics
continuity
health
economics

Keywords

  • Anti-mitotic drug
  • Anti-mitotic protein
  • Bioavailability
  • Cancer
  • KAR-2
  • TPPP/p25

ASJC Scopus subject areas

  • General
  • Mathematics(all)
  • Physics and Astronomy(all)
  • Engineering(all)

Cite this

Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy. / Lehotzky, A.; Tokési, N.; Gonzalez-Alvarez, I.; Merino, V.; Bermejo, M.; Orosz, F.; Lau, P.; Kovacs, G. G.; Ovádi, J.

In: Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences, Vol. 366, No. 1880, 13.10.2008, p. 3599-3617.

Research output: Contribution to journalArticle

@article{8c60e0756d6142f1b5ee81eeae66925c,
title = "Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy",
abstract = "Cancer continues to be one of the major health and socio-economic problems worldwide, despite considerable efforts to improve its early diagnosis and treatment. The identification of new constituents as biomarkers for early diagnosis of neoplastic cells and the discovery of new type of drugs with their mechanistic actions are crucial to improve cancer therapy. New drugs have entered the market, thanks to industrial and legislative efforts ensuring continuity of pharmaceutical development. New targets have been identified, but cancer therapy and the anti-cancer drug market still partly depend on anti-mitotic agents. The objective of this paper is to show the effects of KAR-2, a potent anti-mitotic compound, and TPPP/p25, a new unstructured protein, on the structural and functional characteristics of the microtubule system. Understanding the actions of these two potential effectors on the microtubule system could be the clue for early diagnosis and improvement of cancer therapy.",
keywords = "Anti-mitotic drug, Anti-mitotic protein, Bioavailability, Cancer, KAR-2, TPPP/p25",
author = "A. Lehotzky and N. Tok{\'e}si and I. Gonzalez-Alvarez and V. Merino and M. Bermejo and F. Orosz and P. Lau and Kovacs, {G. G.} and J. Ov{\'a}di",
year = "2008",
month = "10",
day = "13",
doi = "10.1098/rsta.2008.0106",
language = "English",
volume = "366",
pages = "3599--3617",
journal = "Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences",
issn = "0962-8428",
publisher = "Royal Society of London",
number = "1880",

}

TY - JOUR

T1 - Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy

AU - Lehotzky, A.

AU - Tokési, N.

AU - Gonzalez-Alvarez, I.

AU - Merino, V.

AU - Bermejo, M.

AU - Orosz, F.

AU - Lau, P.

AU - Kovacs, G. G.

AU - Ovádi, J.

PY - 2008/10/13

Y1 - 2008/10/13

N2 - Cancer continues to be one of the major health and socio-economic problems worldwide, despite considerable efforts to improve its early diagnosis and treatment. The identification of new constituents as biomarkers for early diagnosis of neoplastic cells and the discovery of new type of drugs with their mechanistic actions are crucial to improve cancer therapy. New drugs have entered the market, thanks to industrial and legislative efforts ensuring continuity of pharmaceutical development. New targets have been identified, but cancer therapy and the anti-cancer drug market still partly depend on anti-mitotic agents. The objective of this paper is to show the effects of KAR-2, a potent anti-mitotic compound, and TPPP/p25, a new unstructured protein, on the structural and functional characteristics of the microtubule system. Understanding the actions of these two potential effectors on the microtubule system could be the clue for early diagnosis and improvement of cancer therapy.

AB - Cancer continues to be one of the major health and socio-economic problems worldwide, despite considerable efforts to improve its early diagnosis and treatment. The identification of new constituents as biomarkers for early diagnosis of neoplastic cells and the discovery of new type of drugs with their mechanistic actions are crucial to improve cancer therapy. New drugs have entered the market, thanks to industrial and legislative efforts ensuring continuity of pharmaceutical development. New targets have been identified, but cancer therapy and the anti-cancer drug market still partly depend on anti-mitotic agents. The objective of this paper is to show the effects of KAR-2, a potent anti-mitotic compound, and TPPP/p25, a new unstructured protein, on the structural and functional characteristics of the microtubule system. Understanding the actions of these two potential effectors on the microtubule system could be the clue for early diagnosis and improvement of cancer therapy.

KW - Anti-mitotic drug

KW - Anti-mitotic protein

KW - Bioavailability

KW - Cancer

KW - KAR-2

KW - TPPP/p25

UR - http://www.scopus.com/inward/record.url?scp=51049090182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51049090182&partnerID=8YFLogxK

U2 - 10.1098/rsta.2008.0106

DO - 10.1098/rsta.2008.0106

M3 - Article

C2 - 18644768

AN - SCOPUS:51049090182

VL - 366

SP - 3599

EP - 3617

JO - Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences

JF - Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences

SN - 0962-8428

IS - 1880

ER -